Serum KL-6 differentiates neuroendocrine cell hyperplasia of infancy from the inborn errors of surfactant metabolism
- M L Doan1,
- O Elidemir1,
- M K Dishop2,
- H Zhang1,
- E O Smith3,
- P G Black4,
- R R Deterding5,
- D M Roberts6,
- Q A Al-Salmi7,
- L L Fan1
- 1Pediatric Pulmonary Section, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA
- 2Department of Pathology, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA
- 3Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
- 4Department of Pediatrics, University of Missouri at Kansas City, Children’s Mercy Hospital, Kansas City, Missouri, USA
- 5Department of Pediatrics, University of Colorado Health Science Center, Children’s Hospital, Denver, Colorado, USA
- 6Pediatric Breathing Disorders Clinic, Anchorage, Alaska, USA
- 7Department of Child Health, Royal Hospital, Oman
- Dr L L Fan, Texas Children’s Hospital, 6621 Fannin, CC1040.00, Houston, TX 77030, USA;
- Received 13 September 2008
- Accepted 2 February 2009
- Published Online First 22 February 2009
Background: The study was conducted in order to determine if the glycoprotein KL-6 is a useful biomarker in differentiating neuroendocrine cell hyperplasia of infancy (NEHI), a benign form of children’s interstitial lung disease, from the more severe inborn errors of surfactant metabolism (IESM), since their clinical presentation can be similar.
Methods: Serum KL-6 levels were measured in 10 healthy control children, 6 with NEHI and 13 with IESM (4 with surfactant protein C (SP-C) and 9 with ABCA3 mutations). The initial clinical presentation, findings on previous CT scans and interstitial lung disease (ILD) scores at the time of KL-6 testing were compared. Correlations of KL-6 levels with age and with interval from lung biopsy were evaluated.
Results: The median (range) KL-6 levels were 265 (1–409), 194 (47–352), 1149 (593–4407) and 3068 (726–9912) U/ml for the control, NEHI, SP-C and ABCA3 groups, respectively. When compared with the control and NEHI groups, median KL-6 levels were significantly higher in the SP-C (p<0.01; p = 0.01, respectively) and ABCA3 groups (p<0.001; p = 0.001, respectively); however, there was no difference between the control and NEHI groups (p = 0.91). An inverse relationship was seen between KL-6 levels and age in the IESM groups, but not in the NEHI or control groups. Children with NEHI had similar presenting clinical features and were equally symptomatic at the time of KL-6 measurement as those with IESM.
Conclusions: Children with NEHI have normal KL-6 levels, in contrast to those with IESM, who have elevated serum KL-6 levels; serum KL-6 may be a useful biomarker in distinguishing between these entities when their clinical presentations overlap.
Competing interests: None.
Ethics approval: This study was approved by the Institutional Review Board of Baylor College of Medicine.